What You Should Know:
- DexCom, Inc., the global leader in real-time continuous glucose monitoring, and Beyond Type 2, a non-profit organization, are joining forces with actress Retta to launch the first-ever National Glucose Awareness Week.
- Taking place from September 23-29, 2024, this initiative aims to bridge the knowledge gap surrounding glucose health and empower individuals to take control of their well-being.
Addressing the Glucose Knowledge Gap
While glucose
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
ECHO Model Proven Effective for Improving Diabetes Care in Rural Areas
- A recent study has shed light on the significant potential of the ECHO Model in improving diabetes care in rural communities.
- The research, published in The Journal of General Internal Medicine, showed that rural healthcare providers participating in weekly ECHO telementoring sessions achieved comparable results to endocrinology specialists in academic medical centers when managing patients with diabetes.
Significant Reduction in A1c Levels
The study, which spanned five years
Read More
CGMs Through Medical Benefits: Improved Adherence and Cost Savings for Diabetes Patients, New Research Shows
What You Should Know:
- A research study by CCS, a leading chronic care management company, reveals that patients receiving continuous glucose monitoring (CGM) devices through medical benefits experience superior adherence and lower costs compared to those accessing them through pharmacy benefits.
- The JMIR Diabetes research — Exploring Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients with Diabetes: Impact of Device Sourcing, highlights
Read More
FDA Clears Eversense® 365: The World’s First One-Year CGM System
What You Should Know:
- Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the FDA has cleared the Eversense® 365 CGM system.
- This marks a significant advancement in diabetes management, offering a fully-implantable, long-term continuous glucose monitoring (CGM) solution for individuals with Type 1 and Type 2 diabetes aged 18 and older.
Eversense 365: Uninterrupted Living with Diabetes
Eversense 365 is set to transform the lives of people with diabetes by
Read More
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
DexCom Launches Non-Prescription Glucose Biosensor in U.S.
What You Should Know:
- Millions of Americans with Type 2 diabetes and prediabetes now have a new option for managing their glucose levels.
- DexCom, a leader in continuous glucose monitoring (CGM) technology announced the launch of Stelo, the first over-the-counter (OTC) glucose biosensor available in the US.
What is Stelo?
Stelo is a small, wearable sensor that provides real-time glucose readings directly to a smartphone app. Unlike traditional blood glucose meters,
Read More
Abbott and Medtronic Partner to Integrate CGM System & Insulin Delivery Devices
What You Should Know:
- Abbott and Medtronic announced a groundbreaking partnership to develop an integrated continuous glucose monitoring (CGM) system designed to seamlessly work with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.
- The strategic collaboration aims to improve diabetes management by enabling more precise insulin dosing and reducing the burden on patients.
CGM System and Insulin Delivery Devices Integration
The new CGM sensor,
Read More
Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable
What You Should Know:
- A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.
- The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community's views on the rapidly growing class of GLP-1 medications, often hailed as
Read More
American Kidney Fund Taps AI Partner to Speed Early Diagnosis of Kidney Diseases
What You Should Know:
- Ubie, a global healthcare AI platform, and the American Kidney Fund (AKF), a leading kidney disease non-profit, have joined forces to improve early detection of kidney disease.
- This strategic collaboration aims to leverage Ubie's AI-powered Symptom Checker and AKF's expertise to empower patients and accelerate diagnosis.
Why Early Diagnosis Matters
Kidney disease is a major health concern, affecting millions in the US. Chronic kidney disease
Read More
Abbott Unveils FreeStyle Libre 3 Plus: World’s Smallest CGM Sensor with Future AID Compatibility
What You Should Know:
- At the American Diabetes Association conference, Abbott unveiled a new addition to its FreeStyle Libre portfolio – the FreeStyle Libre 3 Plus sensor.
- The sensor boasts the distinction of being the world's smallest, thinnest, and most discreet continuous glucose monitoring (CGM) sensor available.
Unmatched Design and Performance
The FreeStyle Libre 3 Plus sensor offers a unique combination of user-centric features:
Unmatched Discreetness: The
Read More
